We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Pipetting Robot Automates COVID-19 Testing Processes to Reduce Repetitive Work and Accidents

By LabMedica International staff writers
Posted on 24 Jun 2020
A new pipetting robot is automating COVID-19 testing processes in European hospitals, thereby significantly reducing the time taken by laboratories to generate results.

The liquid handling robot named flowbot ONE developed by Flow Robotics (Copenhagen, Denmark) makes automating pipetting simple with an intuitive user interface that can be mastered in just one hour. More...
The company has termed flowbot ONE as a liquid handling cobot as it collaborates with the user in the lab, assisting in workflows and adapting to the lab. It does not require programming, extensive training, or a long implementation period. With flowbot ONE, these steps can be skipped and automation can be started immediately. The highly precise system ensures accurate and consistent pipetting and results, saving time as well as increasing safety by minimizing manual handling of pathogenic strains.

A plug and play solution with high accuracy and precision, flowbot ONE allows the user to customize components and liquid classes easily, edit, copy and share existing programs. It offers a range of functions to ease the workflow such as two pipette modules (choice between 1, 4 and 8-channel), volume ranges of 1-20μL, 2-200μL and 10-1000μL, 12 capacity positions (SBS format), and automatic liquid level detection. flowbot ONE has taken over the massive workload of COVID-19 sample preparation in hospitals across Europe.

“Our stress levels have decreased in many ways: less repetitive work, and fewer potential errors. While the robot is pipetting, we can perform other tasks, accelerating the speed of the COVID-19 tests we are performing,” said Martin Friis, a molecular biologist at Herlev Hospital.

Related Links:
Flow Robotics


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.